ZYMEDI
Latest round
- Series A
Last raised
- May 2023
Total raised
- $29M
Investors
- 8
About ZYMEDI
Established in 2019 and based in Incheon, South Korea, Zymedi operates as a biotechnology company that develops pharmaceutical drugs and novel therapeutics for diseases. Sunghoon Kim (CEO) and Nam Hoon Kwon (CTO) are the co-founders of the company. The company provides HOMEOS (AIDD), which is a platform that harnesses knowledge of aminoacyl-tRNA synthetase (ARS) biology to maintain a varied pipeline of medications. The firm has a proprietary database that contains all ARS-related information. The Darsome database provides in-depth investigation of disease-associated ARS genome and proteome alterations, while the Inter-ARS database provides insights into the ARS interactome. Zymedi also makes use of the Ailo database, an AI-based lead optimisation tool for druggable candidates. ZYMEDI's pipeline includes an antibody for pulmonary arterial hypertension (PAH) that specifically targets membrane-exposed lysyl-tRNA synthetase (KARS1). In addition, the company is developing a small-molecule chemical that inhibits KARS1's multifarious proinflammatory activities for the treatment of non-alcoholic steatohepatitis (NASH). Furthermore, ZYMEDI's pipeline includes a pan-KRAS inhibitor targeted to target AIMP2-DX2 in KRAS-mutated tumours.
Who invested in ZYMEDI
8 investors across 2 rounds
See all investors in ZYMEDI
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ZYMEDI
Who invested in ZYMEDI?
ZYMEDI has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ZYMEDI raised?
ZYMEDI has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ZYMEDI last raise money?
ZYMEDI's most recent round on record is a Series A, in May 2023.
What does ZYMEDI do?
Established in 2019 and based in Incheon, South Korea, Zymedi operates as a biotechnology company that develops pharmaceutical drugs and novel therapeutics for diseases.
Where is ZYMEDI headquartered?
ZYMEDI is headquartered in Incheon, South Korea.
Which VCs invest in companies like ZYMEDI?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at ZYMEDI's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ZYMEDI? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.